Clinical trial · Observational
Molecular Analysis of Gastric and OEsophageal Cancers STudy
A Prospective Translational Tissue Collection Study in Early and Advanced Gastric and Oesophageal Cancers to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Never opened to recruitment due to lack of funding
Summary
Brief summary (as posted)
A prospective translational tissue collection study to identify biomarkers predictive of treatment response/resistance and biomarkers of prognostic value from a series of patients who are investigated for and diagnosed with early or advanced gastric/junctional or oesophageal cancer (oesophagogastric cancer) at The Royal Marsden Hospital.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma Esophagus | Esophageal Adenocarcinoma | ALIAS | 0.90 |
| Adenocarcinoma - GEJ | Gastroesophageal Junction Adenocarcinoma | ALIAS | 0.90 |
| Adenocarcinoma of the Stomach | Gastric Adenocarcinoma | ALIAS | 0.90 |
| Squamous Cell Car. - Esophagus | Esophageal Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| biopsy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- early stage curative disease
- interventionNames
- Diagnostic Test: biopsy
- label
- Locally advanced or metastatic disease
- interventionNames
- Diagnostic Test: biopsy
Primary outcomes (1)
- measure
- The prevalence and distribution of biomarkers potentially prognostic or predictive of treatment response/resistance in a large series of patients with OGC
- timeFrame
- 5 years
Secondary outcomes (5)
- measure
- Disease control rate (CR, PR and SD) in locally advanced/metastatic disease
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patient is being investigated/treated for OGC at The Royal Marsden Hospital during the study period. 2. Patient has an oesophageal/gastric mass or metastasis amenable to core needle biopsy or surgery. 3. Patient is clinically fit enough to undergo a tumour biopsy or surgery (if not already performed) according to investigator assessment and local guidelines. 4. Patient is ≥ 18 years of age. 5. Patient is able to understand the information provided within the patient information sheet and is able to provide written informed consent. 6. Patient has sufficient tissue for analysis. Exclusion Criteria: 1. Patients who are not treated at The Royal Marsden Hospital or referring centre. 2. Patients who have a second active malignancy other than oesophageal/gastric cancer. 3. Patients who have one or more contraindications to a tumour biopsy or surgery (if not already performed) according to local guidelines. 4. Patients with an uncontrolled concomitant medical condition including, but not limited to, ongoing or active infection not amenable to standard antibiotic therapy, irreversible increased risk of bleeding which prevents biopsy as per standard procedures, or a psychiatric illness or social situation that could affect compliance with study procedures.
References
Publications (0)
Data not yet available